Ингаляционные глюкокортикостероиды в лечении хронической обструктивной болезни легких

Основными задачами терапии хронической обструктивной болезни легких (ХОБЛ) являются уменьшение выраженности симптомов заболевания и снижение риска обострений. В статье обсуждается роль локального и системного воспаления в патогенезе ХОБЛ, а также различные механизмы фармакологического влияния на него. Рассмотрены подходы к назначению базисной терапии пациентам с ХОБЛ, рекомендуемые различными национальными и глобальными руководствами (клинические рекомендации Российского респираторного общества, критерии Глобальной стратегии по лечению хронической обструктивной болезни легких (Global Initiative for Chronic Obstructive Lung Disease – GOLD), руководство Национального института совершенствования здравоохранения Великобритании (National Institute for Health and Clinical Excellence – NICE)), а также рекомендации по периодичности пересмотра терапии. В настоящее время в мире разрабатываются и регистрируются т. н. тройные комбинации – фиксированные комбинации двойных бронхолитических препаратов с ингаляционными глюкокортикостероидами, при этом их место и значение в лечении ХОБЛ вызывает многочисленные дискуссии. В работе обсуждается роль фиксированных тройных комбинаций при снижении частоты обострений ХОБЛ, воздействии на функциональные и пациент-репортированные исходы, приведены рекомендации по применению тройных комбинаций у пациентов с ХОБЛ с учетом соотношения польза / риск.

1. Barnes P.J., Burney P.G.J., Silverman E.K et al. Chronic obstructive pulmonary disease. Nat. Rev. Dis. Primers. 2015; 1: 15076. https://doi.org/10.1038/nrdp.2015.76.

2. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2020 Report. Available at: https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf [Accessed: May 11, 2020].

3. McDonough J.E., Yuan R., Suzuki M. et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N. Engl. J. Med. 2011; 365 (17): 1567-1575. https://doi.org/10.1056/NEJMoa1106955.

4. Agustí A., Edwards L.D., Rennard S.I. et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: A novel phenotype. PLoS One. 2012; 7 (5): e37483. https://doi.org/10.1371/journal.pone.0037483.

5. Thomsen M., Ingebrigtsen T.S., Marott J.L. et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA. 2013; 309 (22): 2353-2361. https://doi.org/10.1001/jama.2013.5732.

6. Brightling C., Greening N. Airway inflammation in COPD: progress to precision medicine. Eur. Respir. J. 2019; 54 (2): 1900651. https://doi.org/10.1183/13993003.00651-2019.

7. Barnes P.J. Inflammatory endotypes in COPD. Allergy. 2019; 74 (7): 1249-1256. https://doi.org/10.1111/all.13760.

8. Yousuf A., Brightling C.E. Biologic drugs: a new target therapy in COPD? COPD. 2018; 15 (2): 99-107. https://doi.org/10.1080/15412555.2018.1437897.

9. Cui Y., Luo L., Li C. et al. Long-term macrolide treatment for the prevention of acute exacerbations in COPD: a systematic review and meta-analysis. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 3813-3829. https://doi.org/10.2147/COPD.S181246.

10. Cazzola M., Rogliani P., Calzetta L. et al. Impact of mucolytic agents on COPD exacerbations: a pair-wise and network meta-analysis. COPD. 2017; 14 (5): 552-563. https://doi.org/10.1080/15412555.2017.1347918.

11. Pavord I.D., Chanez P., Criner G.J. et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N. Engl. J. Med. 2017; 377 (17): 1613-1629. https://doi.org/10.1056/NEJMoa1708208.

12. Criner G.J., Celli B.R., Brightling C.E. et al. Benralizumab for the prevention of COPD exacerbations. N. Engl. J. Med. 2019; 381 (11): 1023-1034. https://doi.org/10.1056/NEJMoa1905248.

13. Zeiger R.S., Tran T.N., Butler R.K. et al. Relationship of blood eosinophil count to exacerbations in chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. Pract. 2018; 6 (3): 944-954.e5. https://doi.org/10.1016/j.jaip.2017.10.004.

14. Zysman M., Deslee G., Caillaud D. et al. Relationship between blood eosinophils, clinical characteristics, and mortality in patients with COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; 12: 1819-1824. https://doi.org/10.2147/COPD.S129787.

15. Авдеев С.Н., Трушенко Н.В., Мержоева З.М. и др. Эозинофильное воспаление при хронической обструктивной болезни легких. Терапевтический архив. 2019; 91 (10): 144-152. https://doi.org/10.26442/00403660.2019.10.000426.

16. Criner G.J., Martinez F.J., Aaron S. et al. Current controversies in chronic obstructive pulmonary disease. A report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee. Ann. Am. Thorac. Soc. 2019; 16 (1): 29-39. https://doi.org/10.1513/AnnalsATS.201808-557PS.

17. Noell G., Cosío B.G., Faner R. et al. Multi-level differential network analysis of COPD exacerbations. Eur. Respir. J. 2017; 50 (3): 1700075. https://doi.org/10.1183/13993003.00075-2017.

18. Bafadhel M., McKenna S., Terry S. et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am. J. Respir. Crit. Care Med. 2011; 184 (6): 662-671. https://doi.org/10.1164/rccm.201104-0597OC.

19. Mayhew D., Devos N., Lambert C. et al. Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations. Thorax. 2018; 73 (5): 422-430. https://doi.org/10.1136/thoraxjnl-2017-210408.

20. Lin Y.H. Liao X.N., Fan L.L. et al. Long-term treatment with budesonide/formoterol attenuates circulating CRP levels in chronic obstructive pulmonary disease patients of group D. PLoS One. 2017; 12 (8): e0183300. https://doi.org/10.1371/journal.pone.0183300.

21. Yamada M., Ichinose M. The Cholinergic Pathways in Inflammation: A Potential Pharmacotherapeutic Target for COPD. Front. Pharmacol. 2018; 9: 1426. https://doi.org/10.3389/fphar.2018.01426.

22. Jacoby D.B., Yost B.L., Kumaravel B. et al. Glucocorticoid treatment increases inhibitory m(2) muscarinic receptor expression and function in the airways. Am. J. Respir. Cell Mol. Biol. 2001; 24 (4): 485-491. https://doi.org/10.1165/ajrcmb.24.4.4379.

23. Barnes P.J. Role of HDAC2 in the pathophysiology of COPD. Annu. Rev. Physiol. 2009; 71: 451-464. https://doi.org/10.1146/annurev.physiol.010908.163257.

24. Anzalone G., Gagliardo R., Bucchieri F. et al. IL-17A induces chromatin remodeling promoting IL-8 release in bronchial epithelial cells: Effect of Tiotropium. Life Sci. 2016; 152: 107-116. https://doi.org/10.1016/j.lfs.2016.03.031.

25. Singh Sohal S., Soltani A., Reid D. et al. A randomized controlled trial of inhaled corticosteroids (ICS) on markers of epithelial-mesenchymal transition (EMT) in large airway samples in COPD: an exploratory proof of concept study. Int. J. Chron. Obstruct. Pulmon. Dis. 2014; 9 (1): 533-542. https://doi.org/10.2147/COPD.S63911.

26. Lee Y.M., Kim S.J., Lee J.H., Ha E. Inhaled corticosteroids in COPD and the risk of lung cancer. Int. J. Cancer. 2018; 143 (9): 2311-2318. https://doi.org/10.1002/ijc.31632.

27. Barnes N.C., Qiu Y.S., Pavord I.D. et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am. J. Respir. Crit. Care Med. 2006; 173 (7): 736-743. https://doi.org/10.1164/rccm.200508-1321OC.

28. Ozol D., Aysan T., Solak Z.A. et al. The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL-8 levels in stable COPD patients. Respir. Med. 2005; 99 (12): 1494-1500. https://doi.org/10.1016/j.rmed.2005.04.025.

29. Calverley P.M., Anderson J.A., Celli B. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356 (8): 775-789. https://doi.org/10.1056/NEJMoa063070.

30. Kunz L.I.Z., Postma D.S., Klooster K. et al. Relapse in FEV1 decline after steroid withdrawal in COPD. Chest. 2015; 148 (2): 389-396. https://doi.org/10.1378/chest.14-3091.

31. Worth H., Peterson S., Nihlen U., Magnussen H. Improved exercise tolerance with budesonide/formoterol vs placebo and formoterol in COPD patients. Am. J. Respir. Crit. Care Med. 2009; 179: A6193. https://doi.org/10.1164/ajrccm-conference.2009.179.1_MeetingAbstracts.A6193.

32. Calverley P.M., Boonsawat W., Cseke Z. et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 22 (6): 912-919. https://doi.org/10.1183/09031936.03.00027003.

33. Szafranski W., Cukier A., Ramirez A. et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21 (1): 74-81. https://doi.org/10.1183/09031936.03.00031402.

34. Sharafkhaneh A., Southard J.G., Goldman M. et al. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir. Med. 2012; 106 (2): 257-268. https://doi.org/10.1016/j.rmed.2011.07.020.

35. Agusti A., Corradi M., Cohuet G. et al. FORWARD: A study of extrafine beclomethasone/formoterol compared with formoterol alone in patients with severe COPD and a history of exacerbations. Eur. Respir. J. 2013; 42 (Suppl. 57): 762.

36. Oba Y., Lone N.A. Comparative efficacy of inhaled corticosteroid and long-acting beta agonist combinations in preventing COPD exacerbations: a Bayesian network meta-analysis. Int. J. Chron. Obstruct. Pulmon. Dis. 2014; 9 (1): 469-479. https://doi.org/10.2147/COPD.S48492.

37. Bafadhel M., Peterson S., De Blas M.A. et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet. Respir. Med. 2018; 6 (2): 117-126. https://doi.org/10.1016/S2213-2600(18)30006-7.

38. Vestbo J., Anderson J.A., Brook R.D. et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016; 387 (10030): 1817-1826. https://doi.org/10.1016/S0140-6736(16)30069-1.

39. Nannini L.J., Lasserson T.J., Poole P. Combined corticosteroid and long-acting beta2-agonist in one inhaler versus long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012; (9): CD006829. https://doi.org/10.1002/14651858.CD006829.pub2.

40. Suissa S., Ernst P. Precision medicine urgency: The case of inhaled corticosteroids in COPD. Chest. 2017; 152 (2): 227-231. https://doi.org/10.1016/j.chest.2017.05.020.

41. Авдеев С.Н., Айсанов З.Р., Белевский А.С. и др. Перспективы фармакотерапии хронической обструктивной болезни легких: возможности комбинированных бронходилататоров и место ингаляционных глюкокортикостероидов. Заключение Совета экспертов. Пульмонология. 2016; 26 (1): 65-72. https://doi.org/10.18093/0869-0189-2016-26-1-65-72.

42. Short P.M., Williamson P.A., Elder D.H.J. et al. The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting β-agonist therapy in COPD. Chest. 2012; 141 (1): 81-86. https://doi.org/10.1378/chest.11-0038.

43. Lipson D.A., Barnhart F., Brealey N. et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N. Engl. J. Med. 2018; 378 (18): 1671-1680. https://doi.org/10.1056/NEJMoa1713901.

44. Lipson D.A., Barnacle H., Birk R. et al. FULFIL Trial: Once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2017; 196 (4): 438-446. https://doi.org/10.1164/rccm.201703-0449OC.

45. Papi A., Vestbo J., Fabbri L. et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018; 391 (10125): 1076-1084. https://doi.org/10.1016/S0140-6736(18)30206-X.

46. Singh D., Papi A., Corradi M. et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016; 388 (10048): 963-973. https://doi.org/10.1016/S0140-6736(16)31354-X.

47. Vestbo J., Papi A., Corradi M. et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017; 389 (10082):1919-1929. https://doi.org/10.1016/S0140-6736(17)30188-5.

48. Ferguson G.T., Rabe K.F., Martinez F.J. et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet. Respir. Med. 2018; 6 (10): 747-758. https://doi.org/10.1016/S2213-2600(18)30327-8.

49. Pascoe S., Barnes N., Brusselle G. et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir. Med. 2019; 7 (9): 745-756. https://doi.org/10.1016/S2213-2600(19)30190-0.

50. Singh D., Fabbri L.M., Vezzoli S. et al. Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA. Int. J. Chron. Obstruct. Pulmon. Dis. 2019; 14: 531-546. https://doi.org/10.2147/COPD.S196383.

51. Williams N.P., Coombs N.A., Johnson M.J. et al. Seasonality, risk factors and burden of community-acquired pneumonia in COPD patients: a population database study using linked health care records. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; 12: 313-322. https://doi.org/10.2147/COPD.S121389.

52. Lee H.W., Park J., Jo J. et al. Comparisons of exacerbations and mortality among regular inhaled therapies for patients with stable chronic obstructive pulmonary disease: Systematic review and Bayesian network meta-analysis. PLoS Med. 2019; 16 (11): e1002958. https://doi.org/10.1371/journal.pmed.1002958.

53. Brassard P., Suissa S., Kezouh A., Ernst P. Inhaled corticosteroids and risk of tuberculosis in patients with respiratory diseases. Am. J. Respir. Crit. Care Med. 2011; 183 (5): 675-678. https://doi.org/10.1164/rccm.201007-1099OC.

54. Lipworth B.J. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arch. Intern. Med. 1999; 159 (9): 941-955. https://doi.org/10.1001/archinte.159.9.941.

55. Loke Y.K., Cavallazzi R., Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax. 2011; 66 (8): 699-708. https://doi.org/10.1136/thx.2011.160028.

56. Suissa S., Kezouh A., Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am. J. Med. 2010; 123 (11): 1001-1006. https://doi.org/10.1016/j.amjmed.2010.06.019.

57. Izquierdo J.L., Cosio B.G. The dose of inhaled corticosteroids in patients with COPD: when less is better. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 3539-3547. https://doi.org/10.2147/COPD.S175047.

58. Rodrigo G.J., Castro-Rodriguez J.A., Plaza V. Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: a systematic review. Chest. 2009; 136 (4): 1029-1038. https://doi.org/10.1378/chest.09-0821.

59. Sabroe I., Postma D., Heijink I., Dockrell D.H. The yin and the yang of immunosuppression with inhaled corticosteroids. Thorax. 2013; 68 (12): 1085-1087. https://doi.org/10.1136/thoraxjnl-2013-203773.

60. Yawn B.P., Li Y., Tian H. et al. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis. Int. J. Chron. Obstruct. Pulmon. Dis. 2013; 8: 295-304. https://doi.org/10.2147/COPD.S42366.

61. Авдеев С.Н., Трушенко Н.В. Тройная терапия в лечении хронической обструктивной болезни легких. Пульмонология. 2019; 29 (2): 199-206. https://doi.org/10.18093/0869-0189-2019-29-2-199-206.

62. Авдеев С.Н., Невзорова В.А., Куделя Л.М. и др. Вопросы тройной терапии в лечении хронической обструктивной болезни легких. Комментарии к алгоритму. Резолюция Совета экспертов от 13.06.18 (Владивосток). Пульмонология. 2019; 29 (3): 365-374. https://doi.org/10.18093/0869-0189-2019-29-3-365-374.

63. Agusti A., Fabbri L.M., Singh D. et al. Inhaled corticosteroids in COPD: friend or foe? Eur. Respir. J. 2018; 52 (6): 1801219. https://doi.org/10.1183/13993003.01219-2018.

64. Avdeev S., Aisanov Z., Arkhipov V. et al. Withdrawal of inhaled corticosteroids in COPD patients: rationale and algorithms. Int. J. Chron. Obstruct. Pulmon. Dis. 2019; 14: 1267-1280. https://doi.org/10.2147/COPD.S207775.

65. NICE 2019 guideline. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. Available at: https://www.guidelines.co.uk/respiratory/nice-copd-guideline/454912.article [Accessed: May 11, 2020].

66. Vukoja M., Kopitovic I., Lazic Z. et al. Diagnosis and management of chronic obstructive pulmonary disease in Serbia: an expert group position statement. Int. J. Chron. Obstruct. Pulmon. Dis. 2019; 14: 1993-2002. https://doi.org/10.2147/COPD.S214690.

67. Российское респираторное общество. Федеральные клинические рекомендации. Хроническая обструктивная болезнь легких. Available at: http://spulmo.ru/obrazovatelnye-resursy/federalnye-klinicheskie-rekomendatsii [Accessed: December 21, 2019].

68. Vanfleteren L.E.G.W., Ullman A., Nordenson A. et al. Triple therapy (ICS/LABA/LAMA) in COPD: thinking out of the box. ERJ Open Res. 2019; 5 (1): 00185-2018. https://doi.org/10.1183/23120541.00185-2018.